Katherine W Turk, Mark D Knobel, Alexandra Nothern, Garrett Friedman, Hannah Noah, Brendan Campbell, Diana C Anderson, Andreas Charidimou, Andrew Mills, Vanessa Coronel, Nacha Pierre, Beverly V Reynolds, Caroline Wagner, Leanne M Varga, John Roefaro, Laura Triantafylidis, Andrew E Budson
{"title":"An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation.","authors":"Katherine W Turk, Mark D Knobel, Alexandra Nothern, Garrett Friedman, Hannah Noah, Brendan Campbell, Diana C Anderson, Andreas Charidimou, Andrew Mills, Vanessa Coronel, Nacha Pierre, Beverly V Reynolds, Caroline Wagner, Leanne M Varga, John Roefaro, Laura Triantafylidis, Andrew E Budson","doi":"10.1212/CPJ.0000000000200346","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients.</p><p><strong>Recent findings: </strong>To facilitate the implementation and monitoring of lecanemab infusions at our tertiary medical center, we convened an interprofessional team. The team created a number of resources including patient handouts and medical documentation templates as well as systems and processes that are likely to be useful to other clinical care settings and centers.</p><p><strong>Implications for practice: </strong>It is our intent to widely share the resources and processes developed.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340999/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200346","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients.
Recent findings: To facilitate the implementation and monitoring of lecanemab infusions at our tertiary medical center, we convened an interprofessional team. The team created a number of resources including patient handouts and medical documentation templates as well as systems and processes that are likely to be useful to other clinical care settings and centers.
Implications for practice: It is our intent to widely share the resources and processes developed.
期刊介绍：
Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
